Loading
A phase 3 trial of Histrelin in Prostate cancer, run by Endo USA Inc., a Keenova Therapeutics Company, completed.
Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer is a phase 3 interventional study registered as NCT01697384 by Endo USA Inc., a Keenova Therapeutics Company, with 138 participants recorded, started 2000-04 and reaching its primary completion in 2003-08. Interventions recorded: histrelin acetate. Conditions recorded: Prostate Cancer, Adenocarcinoma of the Prostate.
Linked to the drug Histrelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Histrelin, Endo (now Keenova Therapeutics and Par Health), Prostate cancer and the tag pipeline.
Shares Endo (now Keenova Therapeutics and Par Health) and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Histrelin, Prostate cancer and the tag pipeline.
Shares Histrelin, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/